Tularik Inc.
Division of Amgen Inc.
www.tularik.com
Latest From Tularik Inc.
Gilead Partnership With Arcus Brings PD-1, TIGIT Assets To Its IO Portfolio
The 10-year partnership brings Arcus up-front funding with ample earnout opportunities, while Gilead gets extensive opt-in rights and an equity stake it can increase – and potentially a wholly owned dual checkpoint combination.
NGM Aims For Three Drugs In Clinical Trials, Padded By Cash From Merck
Privately held NGM Biopharmaceuticals is investing in another dozen preclinical compounds, fueled in part by a rich deal with Merck & Co. that also enables employee expansion, Jeff Jonker explains in interview.
Deals Of The Week Wonders: Who Will Buy Onyx?
Oncology-focused pharmas and multiple myeloma players, as well as would-be MM competitors, top Wall Street’s list of possible Onyx buyers. A successful deal could aid the longstanding biotech rally that has retrenched in recent weeks.
Financings Of The Fortnight: Third Rock Bets Big on Global Blood Therapeutics’ Allosteric Modulators
Plus news on recent financial activity by Igenica, PhaseBio Pharmaceuticals, Seldar Pharmaceuticals and BioMarin Pharmaceutical.
Company Information
- Industry
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
- Pharmaceuticals
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Amgen Inc.
- Senior Management
-
David V Goeddel, PhD, CEO
Jack Anthony, SVP, Bus. & Comm. Dev.
Mary Jean Stempien, MD, VP, Clinical Dev. - Contact Info
-
Tularik Inc.
Phone: (650) 825-7000
2 Corporate Dr.
S. San Francisco, CA 94080
USA